Project Grant HT94252510173
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$932K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The Johns Hopkins University was awarded a $1,623,356 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from August 1, 2023 to July 31, 2026 to develop CHMP7 antisense oligonucleotide (ASO) therapy to repair nuclear pore and TDP43 dysfunction in sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The Military Medical Research and Development program supports basic, applied, and...
The Department of the Army Medical Command awarded The Johns Hopkins University a $982,500 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Targeting M6A Dysregulation as a Novel Therapeutic Strategy for C9ORF72-ALS". The award period is May 1, 2024 to April 30, 2026. This research aims to develop new treatments for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), with a focus on the C9ORF72 genetic...
The Johns Hopkins University received a $2,455,671.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop an AAV-based gene therapy for amyotrophic lateral sclerosis (ALS). The award, effective June 1, 2024 through May 31, 2027, will enable Johns Hopkins to conduct innovative biomedical research and advance therapeutic solutions for this neurological disorder. The federal grant funding supports the university's...
This $1,137,301 federal Project Grant awarded by the Defense Health Agency on July 1, 2024 supports The Johns Hopkins University's work on "MULTI-MODAL, REMOTE TRACKING OF ALS PROGRESSION USING NOVEL DIGITAL BIOMARKERS" through June 30, 2026. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The project aims to develop...
The U.S. Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $798,272.00 Project Grant to The Johns Hopkins University on March 15, 2025. The grant supports research to test the use of Wnt inhibitors as a therapeutic approach to reverse TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The research will be conducted at Johns Hopkins University in Baltimore, Maryland over a 2-year period, with a...
This Project Grant award of $498,828.00 from the Defense Health Agency supports the development of a novel treatment strategy and unique methods of delivery to the central nervous system for amyotrophic lateral sclerosis (ALS). The award, effective from July 1, 2023 to June 30, 2025, is funded through the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful biomedical...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
The Defense Health Agency awarded Thomas Jefferson University a $779,200 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct senotherapy research for amyotrophic lateral sclerosis (ALS) from April 1, 2023 through March 31, 2025. The grant will support basic, applied, and advanced biomedical research investigating medical solutions for ALS, consistent with the program's goals of transforming military and public health care through innovative...
This $586,740 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will fund research by the Als Therapy Development FND, doing business as A L S Therapy Development Institute, to investigate the pharmacological inhibition of TRAF2- and NCK-interacting kinase (TNIK) as a potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The grant will support the non-profit organization's...
The Johns Hopkins University was awarded an $818,750 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will support research into RNA-based modulation of TDP-43 mislocalization in ALS/FTD with uridine analogs from September 15, 2022 to September 14, 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...